Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$704.89 -7.51 (-1.05%)

(As of 10:45 AM ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
1

Hold
6

Buy
16

Based on 23 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 6 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,052.90
49.37% Upside

According to the 23 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,052.90. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $165.00. The average price target represents a forecasted upside of 49.37% from the current price of $704.89.

Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

REGN Analyst Ratings Over Time

Type	Current Forecast 12/31/23 to 12/30/24	1 Month Ago 12/1/23 to 11/30/24	3 Months Ago 10/2/23 to 10/1/24	1 Year Ago 12/31/22 to 12/31/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	19 Buy rating(s)
Hold	6 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$1,052.90	$1,107.29	$1,118.62	$908.12
Forecasted Upside	49.37% Upside	47.59% Upside	6.85% Upside	3.40% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Elon Spotted at Weird Facility in Memphis? (Ad)

What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date. Because now, he is targeting the world’s most powerful technology… And doing it bigger – and better – than everyone else.

Go here to see what Elon is planning.

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	47.80% Upside	24,181.91% Upside	14.07% Upside
News Sentiment Rating	Neutral News See Recent REGN News	Positive News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	Canaccord Genuity Group 5 of 5 stars	J. Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Underperform	$565.00	-28.30%
11/15/2024	Wolfe Research 3 of 5 stars		Initiated Coverage	Outperform	$1,150.00	+46.96%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$895.00	+11.27%
11/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,150.00 ➝ $1,000.00	+20.56%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,260.00 ➝ $1,215.00	+44.97%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
11/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,235.00 ➝ $1,184.00	+41.27%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,080.00 ➝ $1,065.00	+25.91%
11/1/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,300.00 ➝ $1,190.00	+40.24%
11/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,137.00 ➝ $1,126.00	+33.88%
11/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,242.00 ➝ $1,195.00	+42.57%
10/24/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$1,250.00 ➝ $1,175.00	+24.93%
10/24/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,150.00	+22.16%
10/23/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$1,015.00 ➝ $1,015.00	+7.77%
10/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,050.00	+9.11%
9/24/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$1,175.00 ➝ $1,077.00	-1.37%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,030.00 ➝ $1,200.00	+12.39%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00	+21.95%
3/12/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,125.00	+16.65%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$800.00 ➝ $760.00	+6.13%
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:56 AM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock's future performance.
The current stock price is $778.50, which is significantly lower than its 52-week high of $1,211.20, suggesting potential for price appreciation as the market recovers.
Seventeen analysts have assigned a buy rating to the stock, reflecting confidence in the company's growth prospects and product pipeline.
The company maintains a solid market capitalization of approximately $85.55 billion, which provides stability and resources for ongoing research and development.
Regeneron Pharmaceuticals, Inc. has a low debt-to-equity ratio of 0.09, indicating a strong balance sheet and lower financial risk, which is attractive to investors.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Recent price target reductions by multiple analysts, including Oppenheimer lowering it from $1,150.00 to $1,000.00, may signal concerns about the company's near-term performance.
One analyst has rated the stock with a sell rating, which could indicate potential risks or challenges that investors should consider.
The stock has experienced significant volatility, with a 52-week low of $735.95, suggesting uncertainty in its price movements.
Regeneron Pharmaceuticals, Inc. has a price-to-earnings (P/E) ratio of 19.27, which, while not excessively high, may indicate that the stock is priced for growth, making it vulnerable to market corrections.
Recent downgrades from firms like Leerink Partners, which lowered their rating from "strong-buy" to "hold," may reflect a cautious outlook on the company's future performance.

REGN Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,052.90, with a high forecast of $1,300.00 and a low forecast of $165.00.
: 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There is currently 1 sell rating, 6 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 49.37% based on their 12-month stock forecasts.
: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.
: Regeneron Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, Royal Bank of Canada, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Regeneron Pharmaceuticals less than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.70 while the average consensus rating score for "medical" companies is 2.81. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Kamala’s final humiliation (Ad)

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

This page (NASDAQ:REGN) was last updated on 12/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target